Ketamine

Beyond Marketing Exhibits at the Psychedelic Sciences MAPS Conference, the Largest Psychedelic Gathering in History

Retrieved on: 
Friday, June 30, 2023
Other Science, Technology, FDA, Research, Other Sports, Sports, General Sports, Pharmaceutical, Mental Health, Small Business, Marketing, Communications, Clinical Trials, Professional Services, Biotechnology, Football, Alternative Medicine, Software, Health, Search Engine Marketing, Science, Psilocybin, Medicine, US Food Sovereignty Alliance, Executive, Super Bowl Most Valuable Player Award, Multidisciplinary Association for Psychedelic Studies, DSM-IV codes, Speech, Culture, Green Bay Packers, Beyond, Stanford University, Multimedia, History, Education Directorates, Athlete, Huberman, Neurophysiology, CO, Green Bay Packers Hall of Fame, MDMA, MAPS, MD, CRM, Ketamine, Knowledge, Growth, Johns Hopkins, Principal, Trauma, Conference, Consciousness, Nightclub, Nursing, Pharmaceutical industry, Medical device, Ayahuasca

The Beyond Marketing team recently exhibited and sponsored the Multidisciplinary Association for Psychedelic Studies (MAPS) Psychedelic Sciences Conference, the largest psychedelic gathering in history.

Key Points: 
  • The Beyond Marketing team recently exhibited and sponsored the Multidisciplinary Association for Psychedelic Studies (MAPS) Psychedelic Sciences Conference, the largest psychedelic gathering in history.
  • "Beyond Marketing are subject matter experts in helping us grow and expand our business.
  • Beyond Marketing continues to support growth and awareness efforts around the use of psychedelics.
  • By sponsoring leading-edge conferences such as the Psychedelic Sciences Conference by MAPS, Beyond Marketing is helping to advance the conversation and promote awareness around the promising benefits of these breakthrough treatments.

Mental Health Provider, Heading Health, Secures $4.5M in Series A Extension

Retrieved on: 
Thursday, June 29, 2023
Psilocybin, Depression, Probability, Aetna, TMS, BCBS, Peter Thiel, Quality of life, Tricare, Psychotherapy, Research, Doctor of Philosophy, Cigna, MDMA, Patient, Systems neuroscience, Ketamine, Trauma, Psychiatry, History of Nigerian Americans in Dallas–Fort Worth, Nursing, UnitedHealth Group

AUSTIN, Texas, June 29, 2023 /PRNewswire/ -- Insurance-based mental healthcare provider Heading, specializing in treating patients with depression and trauma has raised $4.5 million in a Series A extension round.

Key Points: 
  • AUSTIN, Texas, June 29, 2023 /PRNewswire/ -- Insurance-based mental healthcare provider Heading, specializing in treating patients with depression and trauma has raised $4.5 million in a Series A extension round.
  • This funding will empower Heading to scale into new markets and invest in its care delivery and analytics platform.
  • "A segregated and one-dimensional mental health system has failed patients, many who wait too long to experience care that offers real and lasting relief.
  • We're proud to have the support of like-minded investors who believe this needs to change," shared Heading CEO & Founder, Simon Tankel.

Soft Reboot Wellness Announces San Francisco Ketamine Infusion Therapy for MDD

Retrieved on: 
Thursday, June 29, 2023
Depression, Diet, United States National Library of Medicine, Research, Brain, Movement, Science, National library, Ketamine, DSM-IV codes, Patient, Synapse, Meditation, BDNF, Mental health, CO2, Pharmaceutical industry

Soft Reboot Wellness has announced that they are offering ketamine infusions for the treatment of major depressive disorder (MDD), anxiety, PTSD, and other mental health struggles for residents in San Francisco.

Key Points: 
  • Menlo Park, California--(Newsfile Corp. - June 29, 2023) - Soft Reboot Wellness' recent announcement gives residents of San Francisco a new therapy option for treatment-resistant depression.
  • The clinic administers low-dose ketamine once a week for four to six weeks, depending on the patient's symptoms and how well they respond to the treatment.
  • To view an enhanced version of this graphic, please visit:
    The wellness clinic's announcement coincides with a study published in the National Library of Medicine.
  • Unlike conventional antidepressants that regulate the patient's neurotransmitters by blocking reuptake, ketamine therapy builds stronger synapses and increases the production of Brain-Derived Neurotrophic Factors (BDNF), explains the clinic.

Stella Expands Trauma Care Offering with Acquisition of Ketamine Therapy Leader Field Trip’s Assets

Retrieved on: 
Tuesday, June 27, 2023
Depression, Nerve, Anxiety, Special, SGB, Psychotherapy, Research, Brain, COVID, PTSI, DSR, Field trip, Acquisition, Patient, Acute stress disorder, Risk, Traumatic brain injury, Ketamine, Special forces, IL, Trauma, Mental health, Pharmaceutical industry, Medical imaging

Stella also offers Ketamine protocols, including the recently awarded SOF Protocol – a treatment reserved for Special Operation Forces who are subject to high risk of brain injury that combines the benefits of ketamine and DSR.

Key Points: 
  • Stella also offers Ketamine protocols, including the recently awarded SOF Protocol – a treatment reserved for Special Operation Forces who are subject to high risk of brain injury that combines the benefits of ketamine and DSR.
  • By acquiring Field Trip’s advanced outcome data, research, technology stack, clinics, and leadership, Stella will enhance its offering of cutting-edge psychedelic therapies alongside its existing services.
  • With the acquisition of Field Trip’s assets, we’re offering patients data-backed treatments that align with our industry leading standards,” said Philippe Sanchez, Chief Executive Officer of Stella.
  • As part of the acquisition, Stella will assume operations of Field Trip clinics in New York, NY, and Washington, D.C., expanding the geographical reach of the DSR protocol.

PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA

Retrieved on: 
Tuesday, June 27, 2023
Partnership, CSE, Depression, Anxiety, Pain, Food and Drug Administration, Ketamine, Hospital, ANDA, Suicidal ideation, FDA, Health Canada, Mental health, Therapy, Food, Pharmaceutical industry

The filing of a Pre-Submission Facility Correspondence will help achieve approval early compared to the standard ANDA approval times.

Key Points: 
  • The filing of a Pre-Submission Facility Correspondence will help achieve approval early compared to the standard ANDA approval times.
  • The Company anticipates KETARX™ approval from the FDA as early as Q1-2024 and commercial launch in the U.S. in Q2-2024 followed by the pursuit of international approvals to support the growing global demand for ketamine.
  • Ketamine is an essential medicine used for anaesthesia and analgesia (pain relief) listed on the WHO Essential Medicines List .
  • A recently published new peer-reviewed study on the real-world effectiveness of ketamine intravenous therapy demonstrated significant patient improvement for depression, anxiety and suicidal ideation.

Icahn School of Medicine at Mount Sinai Dean and Researcher Receives Prestigious Award in Psychopharmacology

Retrieved on: 
Monday, June 26, 2023
Molecular biology, Science, Depression, DSM-IV codes, Genetics, Icahn School of Medicine at Mount Sinai, Schizophrenia, Anxiety, Fear, Psychopharmacology, Cancer, Donald Klein, Research, Mount Sinai, ASCP, Food and Drug Administration Amendments Act of 2007, National academy, Publication, Patent, MD, Patient, Attention deficit hyperactivity disorder predominantly inattentive, Neuroscience, Ketamine, Anne, Mount Sinai Health System, Society, Book, Food, Pharmaceutical industry, Medicine

NEW YORK,  June 26, 2023 /PRNewswire-PRWeb/ -- Dennis Charney, MD, the Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and President for Academic Affairs of the Mount Sinai Health System, has received the prestigious Donald Klein Lifetime Achievement Award from the American Society for Clinical Psychopharmacology (ASCP). The award was presented to Dr. Charney during the ASCP's annual meeting on Wednesday, May 31.

Key Points: 
  • NEW YORK, June 26, 2023 /PRNewswire-PRWeb/ -- Dennis Charney, MD, the Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and President for Academic Affairs of the Mount Sinai Health System, has received the prestigious Donald Klein Lifetime Achievement Award from the American Society for Clinical Psychopharmacology (ASCP).
  • The award was presented to Dr. Charney during the ASCP's annual meeting on Wednesday, May 31.
  • The award is presented annually to an individual who has made an outstanding contribution to the field of clinical psychopharmacology.
  • His work was fundamental not only in shaping the modern understanding of clinical depression, but also in defining the nature of clinical psychopharmacology trials.

Numinus Announces Agreement with HealingMaps to Drive Strategic Clinic Growth

Retrieved on: 
Thursday, June 22, 2023
Psilocybin, Agreement, Good, Ketamine, Traction, TSX, PAT, Entrepreneurship, Mental health, MDMA, Nursing, List of Marvel Comics characters: N

We're pleased to partner with them to drive greater awareness of our services and clinic locations," said Payton Nyquvest, Founder and CEO.

Key Points: 
  • We're pleased to partner with them to drive greater awareness of our services and clinic locations," said Payton Nyquvest, Founder and CEO.
  • As part of the Agreement, Healing Maps will showcase Numinus services and clinics on their platform, and engage with practitioners interested in participating in the Numinus Network as licensees, or furthering their PAT training through Numinus' practitioner PAT certification programs.
  • To learn more about Numinus' Practitioner Training programs, including Certification Pathways for Ketamine, MDMA or Psilocybin-assisted therapies, please see: www.numinus.com/our-training-selection/ .
  • To learn more about HealingMaps and their showcase of Numinus' practitioner training services, please see: www.healingmaps.com/psychedelic-assisted-therapy-training/ .

Osmind Announces Publication of Largest Real-World Study on Effectiveness of Ketamine Intravenous Therapy for Depression, Anxiety and Suicidal Ideation

Retrieved on: 
Tuesday, June 20, 2023
Mental Health, Health, Science, Pharmaceutical, Research, Insurance, Maintenance, Depression, Therapy, Suicide, Anxiety, MS, CDC, KIT, Anxiety disorder, Journal, DSM-IV codes, Patient, Medicine, Ketamine, RWE, Suicidal ideation, FDA, Mental health, McInnes, Journal of Affective Disorders, Pharmaceutical industry, Medical device, MD

The unique study, which is the largest of its kind, specifically found:

Key Points: 
  • The unique study, which is the largest of its kind, specifically found:
    KIT is effective for depression and anxiety.
  • KIT reduced symptoms by at least 50% after six infusions in ~50% of patients for depression and anxiety.
  • The concordance of outcomes between this study and Osmind’s previous study on acute ketamine outcomes ( McInnes et al.
  • Osmind collaborates with the research community to analyze anonymized, aggregated data to advance new diagnostics, therapeutics, and precision medicine approaches.

PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.

Retrieved on: 
Tuesday, June 20, 2023
Partnership, CSE, Marketing, Pain, Ketamine, Hospital, FDA, Therapy, Mental health, Pharmaceutical industry

Ketamine is currently on the FDA’s drug shortage list .

Key Points: 
  • Ketamine is currently on the FDA’s drug shortage list .
  • Outside of the FDA approved indications, ketamine is also being administered in hospitals and clinics to treat various disorders encompassing mental health, neurological and pain.
  • PharmaTher expects to file its abbreviated new drug application (“ANDA”) for KETARX™ (racemic ketamine) with the FDA in early July and obtain FDA approval in Q1-2024.
  • Fabio Chianelli, CEO of PharmaTher, commented: “Our highest priority is to obtain regulatory approvals and commercialize KETARX™ (racemic ketamine) worldwide for unmet medical needs.

Ketamine Clinics Los Angeles (KCLA) Takes Center Stage as The Pioneers of Ketamine Treatment for Mental Health Disorders at MAPS' Psychedelic Science 2023

Retrieved on: 
Thursday, June 15, 2023
KCLA, HOPE, Harvard University, Patient, Outline of health sciences, Environment, Psychology, Cleveland Clinic, University, TMS, Culture, Monash University Faculty of Medicine, Nursing and Health Sciences, Hope, Suicide, Mental, UCLA, Mental health, Anesthesiology, PTSD, Safety, Depression, USC, Ketamine, Cincinnati, Anxiety, Booth, Stanford University, Mandel, Physician, Psychiatry, Society, Nursing, Pharmaceutical industry, New York University, Psychotherapy, Yale University

LOS ANGELES, June 15, 2023  /PRNewswire/ -- Ketamine Clinics Los Angeles (KCLA) unveils a new era in safe and effective mental health care for all —through IV Ketamine Infusion Therapy at Psychedelic Science 2023, the world's largest gathering of psychedelic medicine practitioners, being held in Denver, CO, June 21-23. KCLA cofounders Steven L. Mandel, M.D., President, and CEO Sam Mandel will attend, along with four team members and one of their patients who has found long-term HOPE and healing through their treatment program in ways she never thought possible. They will be at Booth 321.

Key Points: 
  • LOS ANGELES, June 15, 2023 /PRNewswire/ -- Ketamine Clinics Los Angeles (KCLA) unveils a new era in safe and effective mental health care for all —through IV Ketamine Infusion Therapy at Psychedelic Science 2023 , the world's largest gathering of psychedelic medicine practitioners, being held in Denver, CO, June 21-23.
  • "The breakthrough treatments we provide represent a significant step forward in the field of psychedelic medicine and the broader field of mental health care," said Ketamine Clinics Los Angeles Cofounder and CEO Sam Mandel .
  • We approach treatments holistically through a collaborative care model with in-house expertise from multi-specialty physicians in anesthesiology, psychology, and psychiatry to address medical and mental health needs," he said.
  • As a medical pioneer in ketamine therapy since January 2014, KCLA offers a viable solution to the current mental health crisis through the delivery of affordable IV Ketamine Infusion Therapy, Psychiatric Medication Management, Transcranial Magnetic Stimulation (TMS), and other mental health services.